A recent setback due to unexpected safety concern from a phase 2 study to evaluate a STAT3 inhibitor in IPF patients refreshed an old debate regarding the feasibility to develop therapeutics targeting ...

Vicore Pharma Holding AB ( ($SE:VICO) ) just unveiled an announcement. Vicore Pharma Holding AB announced its participation in the Oppenheimer ...

A father of seven was given 'false assurance' by a hospital in England who also failed to tell him he had a terminal lung ...

The FDA has granted orphan drug designation to Birchbiomed’s FS2 as a treatment for idiopathic pulmonary fibrosis, or IPF.

Trevi Therapeutics stock (TRVI) earns a Buy rating as Haduvio advances toward phase 3 for chronic cough in IPF. Read the full ...

The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China Idiopathic pulmonary fibrosis (IPF) ...

VANCOUVER, BC, Dec. 2, 2025 /CNW/ - BirchBioMed Inc., a leading clinical stage biopharmaceutical company, expert in the development of products for scarring and other fibrosis-related disorders and ...

During National Influenza Vaccination Week, experts encourage everyone 6 months and older to get vaccinated to reduce risk of severe illness and hospitalization ARLINGTON, Va. and BETHESDA, Md. and ...

Researching IPF after her late husband's diagnosis meant learning many new acronyms and abbreviations, says guest writer.

Debbie knew she had more life to live.

Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an ...